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ABSTRACT
Interleukin (IL)–12 has antitumor effects in murine studies. To evaluate this clinically, we investigated whether
high levels of circulating IL-12 in patients after allogeneic hematopoietic stem cell transplantation (HSCT) are
associated with improved relapse-free survival. We prospectively studied 134 patients undergoing HSCT.
Median follow-up was 1158 days (range, 70-1792 days). Plasma IL-12 levels were measured before transplan-
tation and on days 0, 4, 7, and 14 after transplantation. The highest levels were seen on days 4 and 7
and were categorized by a cluster analysis of the logarithmically transformed IL-12 concentrations, which were
then correlated with relapse-free survival. Forty-six patients had low levels of IL-12 (median, 2 pg/mL; range,
0-6.5 pg/mL), 49 patients had medium levels (median, 20.5 pg/mL; range, 7-75.5 pg/mL), and 25 patients had
high levels (median, 181 pg/mL; range, 84-623 pg/mL). Patients with high IL-12 levels before transplantation
had the highest increase after transplantation. With a multivariate Cox model for relapse onset, with the low
IL-12 level as the reference, patients in the high–IL-12 group had an adjusted hazard ratio of 0.27 (95%
confidence interval, 0.09-0.79), and medium group patients had a hazard ratio of 0.65 (95% confidence interval,
0.31-1.36). The incidences of relapse at 500 days by Kaplan-Meier analysis by IL-12 group were 23.0% (high
group), 40.3% (medium group), and 48.8% (low group). There was no association between IL-12 levels and the
risk of acute graft-versus-host disease (GVHD; P .51) or chronic GVHD (P .28). In conclusion, high IL-12
levels after HSCT are associated with improved relapse-free survival without increasing the risk for GVHD.
Patients with high pretransplantation IL-12 levels have an increased likelihood of higher posttransplantation
IL-12 levels, possibly because of a host-graft interaction, and this may predispose to better clinical outcomes.
© 2005 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Allogeneic hematopoietic bone marrow and stem
ell transplantation (HSCT) is the treatment of choice
or many hematologic malignancies [1]. However, the
isk associated with this procedure remains a serious
roblem. Patients undergoing allogeneic stem cell
resented at the 46th annual meeting of the American Society of Hema-
eology, San Diego, CA, December 6, 2004.
014ransplantation still have up to 50% treatment-related
ortality [1,2]. The main causes of patient mortality
nd morbidity after transplantation include relapse
nd graft-versus-host disease (GVHD) [3]. The
ain obstacle after HSCT has become eradicating
he malignancy through graft-versus-malignancy or
raft-versus-leukemia (GVL) effects while main-
aining manageable levels of GVHD. Both GVL
nd GVHD seem to be mediated through immune
vents.
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IL-12 and Reduced Relapse after Transplantation
BReﬁning a clinician’s ability to predict conse-
uences on the basis of immune manifestations may
elp in the separation of GVL and GVHD, thus
mproving cancer treatment. We have recently dem-
nstrated that high numbers of circulating dendritic
ells (DCs) after allogeneic HSCT are associated with
mproved relapse-free survival without an increase in
VHD [4]. DCs are professional antigen-presenting
ells that are stimulated by cytokine signals [5]. This
ascade of events leads to DC maturation and release
f immunostimulatory cytokines such as interleukin
IL)–12 [5]. IL-12 is intricately involved in the acti-
ation of naive T cells by DCs [6,7]. Included among
he biological properties of IL-12 are lymphoid devel-
pment, induction of proliferation of T and natural
iller (NK) cells, stimulation of cytokines such as
nterferon , and induction of the maturation of T
elper 1 (Th1) cells, which are critical for innate
mmunity [7,8]. Additionally, IL-12 can act directly on
Cs through an IL-12 receptor and prime the DCs
or subsequent production of IL-12 [9]. Given this key
ole of IL-12 in the activation of both innate and
daptive immunity, IL-12 has been studied in a mu-
ine model of GVHD by Sykes et al. [10]. In this
reclinical model, IL-12 preserves the GVL effect
hile simultaneously inhibiting GVHD [11]. How-
ver, the role of IL-12 in human clinical transplanta-
ion and its effects on cancer relapse and GVHD are
nknown.
On the basis of the preclinical murine data indi-
ating that IL-12 has potential antitumor effects, we
ypothesized that higher IL-12 levels are associated
ith reduced relapse after clinical transplantation. We
nvestigated this association between levels of IL-12
nd relapse-free survival in our study population. We
easured IL-12 levels in the pretransplantation and
arly posttransplantation period according to the ra-
ionale that IL-12 could be a predictive marker for
uture clinical events.
ATERIALS AND METHODS
atients
We prospectively collected blood samples and
linical data from patients undergoing allogeneic
SCT after we obtained University of Florida Insti-
utional Review Board–approved informed consents.
ne hundred thirty-four patients were enrolled, and
4 patients were not evaluable because of inadequate
amples. Of the 120 patients studied, 72 received
ransplants from related donors, and 48 transplants
ere from unrelated donors, including 4 cord blood
ransplants. One hundred sixteen patients were HLA
atched on all 6 antigen loci. Patients were deﬁned as
aving a high disease risk if they had acute myeloge-
ous leukemia and acute lymphoblastic leukemia
B&MTther than ﬁrst complete remission (CR1), primary
nduction failure, acute leukemia from antecedent he-
atologic disorder, chronic myelogenous leukemia
CML) not in ﬁrst chronic phase, chronic lymphocytic
eukemia, acute bilineage leukemia, non-Hodgkin lym-
homa, Hodgkin disease, myelodysplastic syndrome
not refractory anemia or refractory anemia with ringed
ideroblasts), multiple myeloma, eosinophilic leukemia,
r plasma cell leukemia. All others were deﬁned as low
isease risk: acute lymphoblastic leukemia in CR1,
cute myelogenous leukemia in CR1, CML in ﬁrst
hronic phase, myelodysplastic syndrome, refractory
nemia, or refractory anemia with ringed sideroblasts.
Patients were treated with myeloablative (65%) or
onmyeloablative (35%) conditioning regimens by us-
ng institutional protocols or treatment plans. Condi-
ioning regimens were described as myeloablative if
igh-dose therapy was administered. High-dose ther-
py is that after which marrow recovery would not be
xpected without treatment. All other regimens with
educed intensity were deﬁned as nonmyeloablative.
requently used institutional myeloablative condi-
ioning regimens are as follows:
. Busulfan/cyclophosphamide/etoposide: busulfan 0.75 mg/kg
orally every 6 hours (total of 16 doses) days 8 to 5,
etoposide 10 mg/kg intravenously (IV; omit etoposide in pa-
tients 65 years of age) days 4 to 2, and cyclophospha-
mide 60 mg/kg IV days 3 to 2.
. Etoposide/total body irradiation (TBI): TBI 3 times
daily (150 cGy per fraction for 9 fractions) days 6 to
4 and etoposide 60 mg/kg IV day 3.
. Cytarabine/cyclophosphamide/TBI: cytarabine 100 mg/m2
IV days 9 to 5, cyclophosphamide 60 mg/kg IV days
4 to 3, and TBI 550 cGy in the morning on day 0. If
the patient has CML and has not had a splenectomy, the
patient receives splenic radiation at a cumulative dose of
500 cGy to be delivered in 100-rad fractions over 5 days
proceeding TBI.
. Cyclophosphamide plus antithymocyte globulin: cyclo-
phosphamide 50 mg/kg IV days 5 to 2 and anti-
thymocyte gamma globulin (ATGAM) 30 mg/kg IV
days 5, 4, and 3 or Thymoglobulin (Genzyme
Corp., Cambridge, MA).
. Busulfan/cyclophosphamide/ATGAM: busulfan 1 mg/kg
every 6 hours days9 to6, cyclophosphamide 50 mg/kg
IV daily days5 to2, and ATGAM 30 mg/kg IV days
4 to 2.
. Cyclophosphamide/TBI: cyclophosphamide 60 mg/kg IV
days 6 to 5 and TBI days 4 to 1 and day 0.
. Busulfan/cyclophosphamide: busulfan 0.75 mg/kg per
dose orally every 6 hours for 16 doses days 9 to 6,
cyclophosphamide 50 mg/kg IV days 5, 4, and 3,
and ATGAM 30 mg/kg IV days 4, 3, and 2.
. For nonmyeloablative allogeneic transplantation, pa-
tients received ﬂudarabine 30 mg/m2 IV days 7 to
2, ATGAM 10 mg/kg IV or rabbit antithymocyte
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1globulin 4 mg/kg days6 to3, and busulfan 1 mg/kg
per dose orally every 6 hours days 4 and 3.
Alternatively, patients received ﬂudarabine 30
g/m2 IV on days4,3, and2 and TBI 200 cGy on
ay 0. GVHD prophylaxis consisted of tacrolimus or
yclosporin A along with a minidose of methotrexate.
Clinical data included patient survival, disease re-
apse, and grade II to IV acute GVHD and chronic
VHD. Acute GVHD was deﬁned as that occurring
efore day 100, and chronic GVHD was deﬁned as
hat occurring after 100 days after transplantation.
atients were followed up until death, last follow-up
ate, or the study end point of June 18, 2004.
ytokine Measurements
Blood samples were collected before transplanta-
ion, before conditioning, as a baseline; on day 0
before stem cell infusion); and on days 4, 7, and 14
fter transplantation. Plasma was frozen at 20°C
ntil analysis. Plasma IL-12 (p70) levels were mea-
ured by enzyme-linked immunosorbent assay, ac-
ording to standard protocols (Endogen, Rockford,
L). Each sample was tested in duplicate or triplicate,
ccording to sample availability and reproducibility,
nd the average is reported as picograms per milliliter.
he sensitivity of detection was in the range of 1 to
000 pg/mL.
linical End Points
The primary study end point was freedom from
elapse, where relapse is included as the event, exclud-
ng death. The secondary study end points were acute
VHD (grades II to IV), death, a composite outcome
f relapse or death, and chronic GVHD. Clinical data
ere collected from hospital records.
tatistical Methods
A cluster analysis was performed on the loga-
ithmically transformed concentration of IL-12 on
ays 4 and 7 with the highest values to categorize
atients according to IL-12 level. Three levels of
L-12 were categorized on the basis of the cluster
nalysis and were designated as low, medium, and
igh groupings. We used a univariate disjoint clus-
ering method based on minimizing the Euclidean
quared distances of group levels [12]. Kaplan-
eier analyses were then used to examine the asso-
iation of IL-12 concentration groups and to study
he outcomes of freedom from relapse, patient sur-
ival, the composite end point of relapse or death,
nd the incidence of GVHD. Freedom from relapse
odels considered relapse as the only event while
ensoring for death; the composite model consid-
red both relapse and death as events. We also
onstructed multivariate Cox proportional hazard
odels to assess the relationships between cytokine f
016evels and study outcomes, substantiating ﬁndings
n the presence of potential confounding factors.
ovariates in the models were sex match, disease
isk level, donor source (peripheral blood or bone
arrow), related or unrelated transplants, patient
ge (years), and transplantation type (myeloablative
r nonmyeloablative). We tested the trajectory of
L-12 levels from the transplantation date through
he ﬁrst week after transplantation in a repeated-
easures linear model. The model was adjusted for
ransplant source, transplantation type (myeloabla-
ive and nonmyeloablative), and donor relation.
airwise comparisons were conducted for the 3 de-
ned IL-12 groups for the baseline level at the day
f transplantation and for the slope over this period.
e also created a regression model for the dependent
ariable of ﬁrst-week IL-12 level (from day 4 or 7 after
ransplantation) by using the explanatory variables of
ecipient age, graft source, transplantation type, donor-
ecipient relationship, and disease risk. All analyses were
onducted
y using SAS software (version 9.0; SAS Institute,
ary, NC).
ESULTS
L-12 Trajectory and Patient Characteristics
The highest IL-12 levels from baseline precon-
itioning through 2 weeks after transplantation oc-
urred on days 4 to 7 after transplantation. On the
asis of cluster analysis of levels at these time
oints, patients were categorized into 3 distinct
roups: those with low (n  46), medium (n  49),
nd high (n  25) levels of circulating IL-12 (Figure
). The median concentrations of IL-12 cytokine in
hese groups were 2.0 pg/mL (range, 0-6.5 pg/mL),
0.5 pg/mL (range, 7-75.5 pg/mL), and 181.0
g/mL (range, 84-623 pg/mL), respectively. Figure
depicts the IL-12 levels from the pretransplanta-
ion period through 2 weeks after transplantation by
he deﬁned IL-12 groupings. As displayed in the
gure, IL-12 levels were signiﬁcantly increased in
he high–IL-12 group at the pretransplantation pe-
iod and were signiﬁcantly different on the trans-
lantation date. In addition, the slopes of IL-12
evels were signiﬁcantly different among the 3
roups as tested in a multivariate repeated-measures
nalysis. After adjustment for transplantation con-
itioning type (myeloablative and nonmyeloabla-
ive), donor source, disease risk, and related or un-
elated transplant, the slopes of IL-12 levels were
igniﬁcantly different from the transplantation date
hrough day 7 (low versus medium groups, P  .02;
edium versus high groups, P  .01). The effect of
igh, middle, or low pretransplantation IL-12 levels
rom the pretransplantation period was maintained
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IL-12 and Reduced Relapse after Transplantation
Bhroughout the patients’ clinical course despite trans-
lant type, donor relation, disease risk, and transplant
ource, all of which were not signiﬁcantly associated with
he trajectory. Furthermore, when the trajectory of
L-12 was analyzed separately on the basis of myeloab-
ative or nonablative conditioning, the effect was consis-
ent in both groups.
Incorporating disease risk did not substantially
lter results, and disease risk itself was not signiﬁ-
ant (P  .97) for the IL-12 level. The P values
Figure 1. Distribution of IL-12 levels by group as deter
igure 2. IL-12 trajectory by IL-12 grouping (error bars represent
ere statistically signiﬁcant in the adjusted model at the transplanta
ow and medium groups (P  .01). **The slopes of IL-12 were sta
hrough day 7 after transplantation. Pre-Tx, before transplantation.
B&MTomparing levels were the same, nor was the abso-
ute level at week 1 signiﬁcantly different between
igh and low disease risk. A regression model as-
essing factors associated with the level of ﬁrst-week
L-12 indicated that related transplants had a higher
L-12 level (adjusted means: related transplants,
.3; unrelated transplants, 2.2; P  .01). However,
he type of transplant, recipient age, graft source,
nd disease risk had no signiﬁcant association in this
odel. The median follow-up time for this cohort,
by cluster analysis. *Zero values not shown on log axis.
ndard error for each group at each follow-up period). *IL-12 levels
e between the high and medium groups (P  .01) and between the
ly signiﬁcant among the 3 groups from the day of transplantationminedthe sta
tion dat
tistical1017
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1alculated as the time from transplantation to the
ast data collection, was 1158 days (range, 70-1792
ays). Patient and transplant characteristics for the
ntire group and for the 3 distinct IL-12 groups are
haracterized in Table 1.
L-12 and Relapse
For the entire cohort, the 500-day freedom from
elapse was 60.6%. The rates for the IL-12 groups
ere 77.0% (high group), 59.7% (medium group),
nd 51.2% (low group). The log-rank tests comparing
he high–IL-12 group with the low group (P  .08)
nd comparing the high group with the medium
roup (P  .25) were not statistically signiﬁcant in
nivariate analyses. However, when adjusting for po-
ential confounding factors in a Cox proportional haz-
rd model, the high–IL-12 group was statistically sig-
iﬁcantly associated with a reduced hazard (adjusted
able 1. Patient and Transplant Characteristics of IL-12 Groups
Characteristic Overall
atient age, y, mean (SD) 45.0 (12.7)
ex match (%) 61.7
eripheral blood source (%) 62.5
nrelated donor (%) 40.0
yeloablative conditioning (%) 64.2
igh disease risk (%) 88.3
isease, total no. of patients (high-risk number)
Acute bilineage leukemia 1 (1)
Acute lymphoblastic leukemia 12 (10)
Acute myeloid leukemia 26 (24)
Chronic lymphoblastic leukemia 4 (4)
Chronic myeloid leukemia 13 (6)
Hodgkin disease 4 (4)
Myelodysplastic syndrome 13 (11)
Multiple myeloma 11 (10)
Myeloproliferative disease 3 (2)
Non-Hodgkin lymphoma 22 (22)
Plasma cell leukemia 1 (1)
Renal cell carcinoma 1 (1)
igure 3. Adjusted freedom from relapse by IL-12 group. The mo
onor relation.
018azard ratio [AHR], 0.27; 95% conﬁdence interval,
.09-0.79; P  .017; Figure 3; Table 2). The Kaplan-
eier adjusted freedom from relapse for the IL-12
roups is displayed in Figure 3. By stratifying the
odel by the transplantation procedure type, we
ound a similar relationship in both groups, although
his was not statistically signiﬁcant. For myeloablative
ransplantations, the high–IL-12 group had a lower
isk for relapse (AHR, 0.25; P  .09), and for nonab-
ative transplantations, a similar effect was noted
AHR, 0.39; P  .23). In a similar fashion, in the
nalysis for peripheral blood graft source transplant
atients, high IL-12 had a protective effect (AHR,
.36; P  .08).
L-12 and GVHD, Death, or Relapse
The overall patient survival rate at 500 days after
ransplantation was 50.3%; by IL-12 groups, the rates
IL-12 Group
(n  46) Medium (n  49) High (n  25)
.3 (12.9) 44.3 (12.7) 47.6 (12.7)
58.7 65.3 60.0
41.3 71.4 84.0
65.2 26.5 20.0
63.0 69.4 56.0
91.3 85.7 88.0
0 (0) 0 (0) 1 (1)
6 (5) 6 (5) 0 (0)
4 (14) 14 (12) 8 (8)
2 (2) 2 (2) 0 (0)
3 (2) 5 (2) 5 (2)
2 (2) 0 (0) 2 (2)
3 (2) 5 (4) 5 (5)
5 (5) 5 (5) 1 (0)
0 (0) 2 (2) 1 (0)
0 (10) 9 (9) 3 (3)
1 (1) 0 (0) 0 (0)
0 (0) 1 (1) 0 (0)
adjusted for sex match, disease risk, graft source, patient age, andLow
44
1
1del was
w
a
s
s
o
p
G
b
p
i
I
c
5
m
T
l
6
l
t
G
D
a
r
a
a
h
f
p
t
c
ﬁ
a
m
e
I
e
a
i
p
d
t
c
c
t
[
i
p
s
d
p
a
i
n
c
m
t
w
l
C
c
a
G
s
m
[
c
b
c
r
T
f
S
H
P
P
U
M
M
H
C
*
T
P
C
A
C
C
*
IL-12 and Reduced Relapse after Transplantation
Bere 59.4% (high group), 50.9% (medium group),
nd 49.4% (low group). There was no signiﬁcant as-
ociation between IL-12 group and 500-day patient
urvival (P .71). A multivariate analysis of secondary
utcomes that compared IL-12 groups with death, com-
osite death or relapse, acute GVHD, and chronic
VHD revealed a statistically signiﬁcant association
etween high levels of IL-12 and the composite end
oint of death or relapse (AHR, 0.37; 95% conﬁdence
nterval, 0.17-0.80; P  .012; Table 3). In addition to
L-12, disease risk was a signiﬁcant risk factor for the
omposite end point of relapse or death (hazard ratio,
.4; P  .005). These results were adjusted for sex
atch, patient age, graft source, and donor relation.
here was no signiﬁcant association between IL-12
evels and risk of acute GVHD, with incidence rates of
0.2%, 72.9%, and 63.2% in the high–, medium–, and
ow–IL-12 groups, respectively (P  .51). Similarly,
here was no association between IL-12 and chronic
VHD (P  .28).
ISCUSSION
Our study suggests that high levels of IL-12 are
ssociated with improved freedom from relapse and
elapse-free survival after HSCT. In a multivariate
nalysis, high IL-12 levels were independently associ-
ted with a reduced incidence of relapse. Patients with
igh levels of IL-12 were also signiﬁcantly protected
able 2. Multivariate Analysis by Cox Proportional Hazard Model
or IL-12 Levels and Outcome of Relapse Onset
Variable
Adjusted
Hazard
Ratio 95% CI
P
Value
ex match 0.64 0.33-1.23 .180
igh disease risk 3.27 0.75-14.20 .114
eripheral blood graft source 1.66 0.57-4.89 .354
atient age (per year) 1.01 0.99-1.04 .363
nrelated transplant 0.90 0.36-2.64 .846
yeloablative conditioning 0.74 0.33-1.68 .475
edium–IL-12 group* 0.65 0.31-1.36 .253
igh–IL-12 group* 0.27 0.09-0.79 .017
I indicates conﬁdence interval.
Low–IL-12 group as reference level.
able 3. Multivariate Analysis: Association of IL-12 with Secondary O
Outcome
Medium–IL-12 G
Adjusted
Hazard Ratio* 95% C
atient death 0.92 0.52-1.6
omposite death or relapse 0.85 0.50-1.4
cute GVHD 1.12 0.65-1.9
hronic GVHD 0.92 0.46-1.8
I indicates conﬁdence interval.
Low–IL-12 group as reference; also adjusted for sex match, disease risk,
B&MTor the composite outcome of relapse or death com-
ared with those with low levels. Furthermore, pa-
ients with high levels of IL-12 did not have an in-
rease in acute or chronic GVHD. These data parallel
ndings in previous animal models, in which IL-12
dministered around the time of transplantation in a
urine model was demonstrated to preserve GVL
ffects while inhibiting GVHD [10,11,13].
Our results are striking in that high circulating
L-12 levels were associated with GVL effects without
xacerbation of GVHD. The mechanisms of IL-12’s
ntitumor effects may be explained by several recent
n vitro and in vivo preclinical studies. As mentioned
reviously, Sykes et al. [10] and Yang et al. [11] have
emonstrated in murine models that IL-12 preserves
he GVL effects against leukemia through CD8 T
ells while inhibiting CD4-dependent GVHD. IL-12
an enhance T-cell proliferation and is the main cy-
okine involved in the regulation of Th1 lymphocytes
7,14]. Further studies of IL-12 at a cellular level
ndicate that the production of IL-12 by antigen-
resenting cells is a crucial initiating step for antigen-
peciﬁc immune responses [7]. IL-12 effects are me-
iated by activation of Th1 cells and by interferon 
roduced by NK cells and activated T cells [13]. Par-
doxically, IL-12 administered exogenously can be
nhibitory to T-cell responses, thus leading to immu-
osuppression [10]. There is both experimental and
linical evidence that GVL and GVHD may be im-
unologically distinct. In murine studies of transplan-
ation, GVL effects without an increase in GVHD
ere found to be associated with increased IL-12
evels, increased peripheral NK 1.1 cells, and the
D4/CD8 lymphocyte ratio [15]. Similarly, stem
ells from donors immunized with host antigens were
ble to induce GVL effects without exacerbation of
VHD through a Th1 cytokine proﬁle with IL-12
ecretion [16]. Furthermore, murine studies with ad-
inistration of regulatory CD4 and CD25 T cells
17], CD8 NK T cells [18], or CD28 and CD40
ostimulatory blockade [19] document that GVL may
e separated from GVHD. It is important to note that
linical observations support the existence of GVL
eactions [20,21]. Therefore, our observations that
High–IL-12 Group
P Value
Adjusted
Hazard Ratio* 95% CI P Value
.773 0.54 0.25-1.19 .128
.549 0.37 0.17-0.80 .012
.691 0.83 0.42-1.66 .594
.813 0.64 0.28-1.46 .284utcomes
roup
I
3
5
4
3patient age, graft source, and donor relation.
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1L-12 is associated with reduced relapse without en-
ancing GVHD suggest that IL-12 may play a critical
ole clinically in the separation of GVL and GVHD.
The mechanisms by which IL-12 may be involved
ith improved relapse-free survival require further
nvestigation. Our recent studies have demonstrated
hat low DC numbers (4.97/L) reconstituted at the
ime of engraftment in transplant patients have an
ndependent role in predicting relapse, survival, and
cute GVHD [4]. Biologically, IL-12 is produced by
K cells and antigen-presenting cells, including DCs.
arly release of IL-12 within the ﬁrst week after con-
itioning and allogeneic cell infusion may act as a
rowth factor for DCs. Indeed, Grohmann et al. [9]
llustrated that DCs express an IL-12 receptor that
ay prime the cell for subsequent production of IL-
2. Because higher DC counts have been recently
ound by our group to be protective against relapse
4], high levels of circulating IL-12 in our patients
ay be involved as a growth factor in the expansion of
Cs at the time of engraftment. Clinically, it is un-
lear at this time whether high levels of IL-12 lead to
mproved DC reconstitution, thus leading to better
utcomes, and we are currently pursuing such studies.
dditional mechanisms of IL-12–induced antitumor
ffects may be mediated by NK cells, as demonstrated
y a recent report in which NK cells exposed to IL-12
isplayed strong cytolytic activity against various tu-
or cells [22]. Recently, Pelloso et al. [23] examined
he efﬁcacy of recombinant human IL-12 administra-
ion to autologous transplant patients. Results showed
marked expansion of major human lymphocyte sub-
ets during treatment. Collectively, on the basis of the
bove-mentioned in vitro and in vivo studies, IL-12
ay have potent antitumor effects through its action
n several immune cells.
Our results are remarkable in that patients with a
redisposition to high IL-12 secretion before trans-
lantation are at an increased likelihood of higher
osttransplantation levels of IL-12. This suggests that
osttransplantation IL-12 levels may not be a function
f the graft alone but may also be a function of the
ecipient to stimulate the graft to produce more IL-12
rom host-graft interaction. Several pretransplanta-
ion factors, such as diagnosis, prior chemotherapy
egimens, and disease status at transplantation, may
nﬂuence IL-12 levels. In addition, data are emerging
o support the hypothesis that a cytokine genetic pre-
isposition of the host may affect clinical outcomes
24]. Additional support for this host-graft interaction
as been well documented in animal models demon-
trating an interaction between damaged host tissues
rom conditioning and correlating with acute GVHD
25,26]. To further elucidate the effects of condition-
ng on the production of IL-12 in our patients, we
tudied the IL-12 trajectory in myeloablative and
onablative recipients separately. The effects of IL-12
020ere strong in both groups, thus further supporting
he hypothesis that hosts predisposed to high IL-12
roduction may interact with the donor graft and
urther increase IL-12 levels and suggesting a host-
raft interaction that is independent of conditioning.
Our rationale for studying the effects of IL-12 is due
o its documented role in murine models promoting
ntileukemia effects while alleviating GVHD [13,27].
herefore, we tested the role of circulating IL-12 in
he immediate posttransplantation period, and this is
he ﬁrst human conﬁrmation of the association be-
ween IL-12 and relapse. A potential advantage of
L-12 testing is its prognostic applicability to the clin-
cal setting. IL-12 measurements as early as the ﬁrst
eek after transplantation have the advantage of de-
ecting patients at high risk of relapse; therefore, they
ay be of predictive value to tailor targeted treat-
ents before relapse. For example, patients with low
L-12 levels may be considered for earlier weaning of
mmunosuppression to promote GVL effects. Further
tudies may be justiﬁed in evaluating IL-12 in the
rophylaxis or treatment of relapse after allogeneic
ransplantation.
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